Drug Trial Radar · NCT07392866
A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma
Last checked: Nov 19, 2026Latest source record: Feb 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Mar 1, 2026
Primary completion
Mar 1, 2030
Study completion Mar 1, 2030
Sponsor
- Lead sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy and safety of the combination therapy of SH006 injection in the treatment of advanced hepatocellular carcinoma
Conditions
- Hepatocellular Carcinoma (HCC)
Interventions
SH006Drug
15 mg/kg administered as IV infusion on Day 1 of each 21-day cycle
BevacizumabDrug
15 mg/kg administered as IV infusion on Day 1 of each 21-day cycle
Oxaliplatin injectionDrug
85 mg/m2 administered as IV infusion on Day 1 of each 21-day cycle
CapecitabineDrug
1000 mg/m2 orally twice daily for 14 days continuous dosing followed by a 7-day break of each 21-day cycle
RegorafenibDrug
160 mg orally once daily for 21 days continuous dosing followed by a 7-day break of each 28-day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS) (Phase II)Time frame: Up to approximately 4 years
- Incidence of Adverse Events (AEs) (Phase II)Time frame: Up to approximately 4 years
- Overall Survival (OS) (Phase III)Time frame: Up to approximately 4 years
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Nanjing Tianyinshan Hospital
Nanjing, Jiangsu, China
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.